RxDoctor Payments Data

Laura McDermott

Nurse Practitioner · Norwich, NYNPI 1629122429

Payments from drug & device makers

$1,376in general payments, 2019–2025

Across 68 payments — averaging $20.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$167
  • AbbVie$153
  • Lilly USA, LLC$141
  • Viiv Healthcare Company$121
  • Pfizer$120
  • Teva Pharmaceuticals USA, Inc.$120
  • plus $555 from 9 others

What the payments were for

  • Food & beverage$1,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,376 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$19,263
Medicare patients
217
Services billed
458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$18,375
VascepaIcosapent Ethyl11$3,928
Albuterol Sulfate HfaAlbuterol Sulfate68$1,830
Fluticasone Propionate142$1,646
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst60$783
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav70$768
Methylprednisolone99$576
Gabapentin33$504
Omeprazole28$462
Doxycycline Hyclate31$354
Ibuprofen35$327
Carvedilol19$302
Azithromycin96$280
Clindamycin Hcl18$212
Levothyroxine Sodium11$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$108$18,37519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Norwich

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →